The expression of the purinergic receptor subtype P2X 7 R, a nonselective cationic channel activated by high levels of adenosine triphosphate (ATP), has been studied in adult microglia obtained from Alzheimer disease (AD) and nondemented (ND) brains, in fetal human microglia exposed to AA 1-42 peptide and in vivo in AA 1-42 -injected rat hippocampus. Semiquantitative reverse transcriptaseYpolymerase chain reaction showed enhanced expression (increase of 70%) of P2X 7 R in AD microglia compared with ND cells (analysis of 6 AD and 8 ND cases). Immunohistochemical analysis showed prominent P2X 7 R expression in association with AA plaques and localized to HLA-DR-immunoreactive microglia. In cultured fetal human microglia, cells exposed to AA 1-42 (5 KM for 18 hours) had significantly elevated levels of P2X 7 R (by 106%) compared with untreated cells. Amplitudes of Ca 2+ responses in these cells, induced by the selective P2X 7 R agonist BzATP, were increased by 145% with AA 1-42 pretreatment relative to control (no peptide pretreatment) and were largely blocked if the P2X 7 R inhibitor-oxidized ATP (oxATP) was added with peptide in pretreatment solution. In vivo, double immunostaining analysis showed considerable P2X 7 R colocalized with microglia after injection of AA (1 nmol) into rat hippocampus. The overall results suggest roles of P2X 7 R in mediating microglial purinergic inflammatory responses in AD brain.
INTRODUCTION
Increased extracellular levels of adenosine triphosphate (ATP) are associated with cellular damage in brain pathology. Leakage of ATP from damaged cells serves as a chemotactic gradient and signal for mobilization and activation of microglia, the immune responding cells of the brain. On activation, microglia express and produce a diversity of factors, which, in assemblage, constitute an inflammatory response to help resolve the original damage. However, this response has the potential of either aiding in the promoting of cell survival to repair injury or, in extreme cases, possibly exacerbating the neuronal damage. The net outcome of the inflammatory response is likely dependent on a number of factors, including the local concentration of ATP and the duration and nature of the initial damage. Presumably, higher and chronic levels of ATP could be indicative of more severe cell damage, thus favoring a proinflammatory response from microglia.
Purinergic receptors comprise the metabotropic P2YR family and the ionotropic P2XR family (1) . The P2YR are G-protein coupled to inositol triphosphate-mediated calcium (Ca 2+ ) release from endoplasmic reticulum stores. Depletion of Ca 2+ from stores leads to a secondary entry of Ca 2+ through store-operated channels located in plasmalemmal membrane. The P2XR family comprises P2X 1 R-P2X 7 R and are directly coupled to nonselective cationic channels allowing influx of Na + and Ca 2+ , efflux of K + , and a net cell depolarization. Functional interactions between the 2 subtypes of purinergic receptors have been reported in human microglia with cell depolarization mediated by ATP binding to a subtype P2XR (not P2X 7 R) acting to inhibit influx of Ca 2+ through store-operated channels subsequent to ATP activation of P2YR (2, 3) .
A particularly unique member of P2XR is P2X 7 R that, when activated by ATP binding, forms a large pore allowing entry of large hydrophilic cationic molecules. The results from a number of studies have suggested that extracellular levels of ATP in excess of 1 mM are generally required for activation of P2X 7 R (3Y5). The high concentration of ATP required to open channels could indicate that functional responses mediated by P2X 7 R are associated with ongoing cellular damage and chronic brain inflammation. In this regard, activation of P2X 7 R in microglia has been correlated with production of the proinflammatory cytokines tumor necrosis factor-> (TNF->) (5) and interleukin-1A (IL-1A) (6, 7) and also with cell apoptosis (8, 9) . Recent work has documented roles of P2X 7 R in the microglial production of superoxide and that expression of the receptor is upregulated in a transgenic mouse model of Alzheimer disease (AD) (10) .
In this study, we have compared the expression of P2X 7 R in microglia obtained from neuropathologically assessed AD brain (6 cases) and nondemented (ND, 8 cases). In addition, we have compared expression of this subtype ionotropic receptor between amyloid-A peptide (AA )-treated and untreated cultured fetal human microglia. Calcium responses induced by the P2X 7 R ligand BzATP have also been determined in untreated microglia or cells previously exposed to AA . Finally, we have measured expression of P2X 7 R in AA 1-42 -injected rat hippocampus.
MATERIALS AND METHODS

Adult Human Microglia
Adult brains were obtained postmortem from individuals who had signed informed consent forms for brain donation to the Brain Donation Program of the Sun Health Research Institute (11) . Neuropathologic analysis was carried out on all donated brains with diagnosis of AD using criteria established in the Consortium to Establish a Registry for Alzheimer_s disease. Nondemented brain was characterized by plaque and tangle scores inconsistent with AD and a lack of clinical dementia in donor individuals. Postmortem intervals for isolation of ND and AD brains were 2.8 T 0.5 hours (n = 8 cases) and 2.1 T 0.2 hours (n = 6 cases), respectively; these times were not significantly different.
Cultured adult human microglia were obtained from brain tissue following published procedures (12, 13) . As noted, isolation of ND and AD brains were carried out within 3 hours postmortem. Immediately after the isolation procedure, brain tissue was enzymatically dissociated and microglia were harvested and placed under culture conditions following standard protocols (14) . Briefly, microglia were separated from other glial cells by differential adherence and maintained in Dulbecco_s modified Eagle medium (DMEM) with high glucose (5 mg/mL) containing 10% fetal bovine serum (Hyclone, Salt Lake City, UT) and 50 Kg/mL gentamicin. Microglia were used in experiments after 10 to 14 days in culture and cell purity was assessed by using immunocytochemistry with antibodies to CD11b (American Type Culture Collection [ATCC], Manassas, VA) to class II major histocompatibility antigen (HLA-DR) (1:800; ICN Pharmaceuticals, Irvine, CA) and to CD68 (1:1000; Accurate Chemical and Scientific Corp. Westbury, NY). Antibody to glial fibrillary acidic protein (GFAP, 1:5,000; Dako, Raleigh, NC) was used to measure astrocyte contamination. Immunocytochemical results showed purity of microglia was in excess of 98%.
Fetal Human Microglia
Fetal cells were obtained from embryonic tissue after legalized therapeutic abortions as certified by the Ethics Committee of the University of British Columbia. The overall procedures of isolation and identification of microglia have been previously described (15) . In brief, brain tissues of 12 to 18 weeks_ gestation were incubated in phosphate-buffered saline (PBS) with 0.25% trypsin and DNase I (40 Kg/mL) for 30 minutes at 37-C. Cells were separated into single cells by repeated gentle pipetting. Dissociated cells were then maintained in T75 flasks in DMEM containing 5% horse serum, 5 mg/mL glucose, 20 Kg/mL gentamicin, and 2.5 Kg/mL amphotericin B. Floating microglia in a medium were harvested after 7 to 10 days and subsequently plated on 6-well multiplates for reverse transcriptaseYpolymerase chain reaction. CD11b and ricinus communis agglutinin, specific markers for microglia, were used to confirm purity of the cultures exceeded 98%.
Preparation and In Vitro and In Vivo Application of Amyloid-A Peptide
Full-length peptide (AA ) was obtained from California Peptides (Napa, CA). Aggregated peptide for microglial stimulation was prepared following procedures outlined previously (16) . Aggregated AA was dissolved in 35% acetonitrile (Sigma, St. Louis, MO) and diluted to 1.5 mM with sterile water. Sequential additions of PBS with vortexing of solutions were used to prepare a peptide concentration of 0.5 mM. A final step was to maintain peptide solution at 37-C for 18 hours to enhance fibril formation and aggregation before storage at Y20-C. Reverse peptide AA 42-1 (California Peptides) was also used in some experiments with preparation following that described for AA .
Forward and reverse peptides were applied in vitro to cultured fetal human microglia. The studies used 18-hour exposure of cells to 5 KM concentrations of peptides. A similar treatment protocol has been applied to human microglia in testing for cellular expression and production of a spectrum of inflammatory mediators (17) .
For in vivo studies, male Sprague-Dawley rats (250Y280 g; Charles River Laboratories, St. Constant, Quebec, Canada) were anesthetized with intraperitoneal injection of a mixture of ketamine hydrochloride (72 mg/kg; Bimeda-MTC, Cambridge, Ontario, Canada) and xylazine hydrochloride (9 mg/kg; Bayer Inc., Etobicoke, Ontario, Canada) and then mounted in a stereotaxic apparatus (Kopf Instruments, Tujunga, CA). AA or AA 42-1 (1 nmol in 2 KL) or PBS was slowly injected (0.2 KL/minute) into the superior blade of dentate gyrus of the hippocampus (anteroposterior: j3.6 mm; mediolateral: j1.8 mm; dorsoventral: j3.2 mm) with a 10-KL Hamilton syringe. All animal procedures were approved by the University of British Columbia Animal Care Ethics Committee adhering to guidelines of the Canadian Council on Animal Care.
Reverse TranscriptaseYPolymerase Chain Reaction Analysis
Fetal human microglia were plated on 6-well multiplates and were exposed to AA or reverse peptide AA 42-1 (applications at 5 KM for 18 hours) or PBS. Adult microglia from ND individuals and patients with AD were also used for reverse transcriptaseYpolymerase chain reaction (RT-PCR) experiments. Isolation of RNAs was performed using TRIzol (Gibco-BRL, Gaithersburg, MD) and DNA contamination was eliminated using DNase. Complementary DNA synthesis was carried out using M-MLV reverse transcriptase (Gibco-BRL).
For in vivo RT-PCR analysis, animals were deeply anesthetized and killed by decapitation at 3 days postinjection of AA , reverse peptide AA 42-1 , or PBS. After removal of brains, tissue samples from hippocampus were prepared and frozen in liquid nitrogen. Total RNA was extracted using TRIzol subjected to DNase I treatment and complementary DNA synthesis carried out using M-MLV reverse transcriptase. M-MLV was omitted as a negative control. PCR primer sequences with expected product size are as follows: human P2X 7 R sense 5 ¶-ACAATGTTGAGAAACGGAC-TCTGA-3 ¶ and human P2X 7 R antisense 5 ¶-CCGGCT-GTTGGTGGAATCCACATC-3 ¶ (728 bp); rat P2X 7 R sense 5 ¶-AGGAGCCCCTTATCAGCTCT-3 ¶ and rat P2X 7 R antisense 5 ¶-CATTGGTGTACTTGTCGTCC-3 ¶ (692 bp); human GAPDH sense 5 ¶-CCATGTTCGTCATGGGTGT-GAACCA-3 ¶ and human GAPDH antisense 5 ¶-GCCAGTA-GAGGCAGGGATGATGTTC-3 ¶ (251 bp); and rat A-actin sense 5 ¶-GTGGGGCGCCCCAGGCACCA-3 ¶ and rat A-actin antisense 5 ¶-GTCCTTAATGTCACGCACGATTTC-3 ¶ (526 bp).
PCR conditions were as follows: initial denaturation at 95-C for 6 minutes followed by 35 cycles of denaturation at 95-C for 45 seconds, annealing at 60-C for 1 minute, and extension at 72-C for 1 minute. A final extension was carried out at 72-C for 10 minutes. The amplified PCR products were identified using 1.5% agarose gels containing ethidium bromide and visualized under ultraviolet light. The intensities of each band were measured by densitometry using the NIH Image J 1.24 software (National Institutes of Health, Bethesda, MD) and expressed as relative mRNA levels (P2X 7 R mRNA levels normalized to GAPDH or A-actin) (17). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and A-actin were used as reaction standards for human and rat, respectively.
Calcium Sensitive Fluorescence Microscopy
The procedures used for measurement of intracellular Ca 2+ [Ca 2+ ] i have been documented (18) . In brief, microglia were incubated with fura-2/AM (acetoxymethyl ester, at 1 KM; Molecular Probes, Eugene, OR) plus pluronic acid (at 1 KM) in normal physiological saline solution (PSS) for 30 minutes. PSS contained (in mM): NaCl (126), KCl (5), MgCl 2 (1.2), HEPES (10), D-glucose (10), and CaCl 2 (1); pH of 7.4. All reagents were obtained from Sigma-Aldrich (St. Louis, MO). After a 20-minute wash in dye-free PSS, coverslips were placed on the stage of a Zeiss Axiovert inverted microscope using a Â40 quartz objective lens. Cells were exposed to alternating excitation wavelengths of 340 nm and 380 nm at 6-second intervals and emission light was passed through a 510-nm filter. An imaging system (Empix Imaging, Mississauga, ON, Canada) was used to record fluorescence ratios using a CCD camera (Retiga 1300i, Burnaby, BC, Canada). Results are presented as ratios F340/F380 versus time with all experiments done at room temperature (RT, 20Y22-C).
Immunohistochemistry of Human Brain
All human samples were obtained from the Brain Bank at the Sun Health Research Institute (Sun City, AZ). The procedures for immunohistochemistry in human tissues were conducted according to previously described methods (19) . In brief, immunohistochemistry for localization of antigens was carried out on 20-Km free-floating tissue sections using single and 2 color procedures as described (19) . The antibody to P2X 7 R (Alomone Laboratory, Jerusalem, Israel) was used at 1:250 first and detected with nickel enhanced diaminobenzidine substrate (19) to give a blue reaction product; sections were subsequently reacted with 3D6 (antibody to N-terminal AA peptide, 1:3,000; provided by Elan Pharmaceuticals, South San Francisco, CA) or with LN3 (1:500; MP Biochemicals, OH), and then reacted with DAB substrate without nickel to give a brown reaction product.
Immunohistochemical Analysis of Rat Brain
Animals were deeply anesthetized and then transcardially perfused with heparinized cold saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (0.1 M PB, pH 7.4). The brains were removed from the skull and postfixed in the same fixative solution overnight and then placed in 30% sucrose for cryoprotection. The brains were then frozen in powdered dry ice and stored at Y70-C. Coronal sections throughout the hippocampus were cut at 40-Km intervals on a cryostat. The sections were stored in cryoprotectant solution. For P2X 7 R expression, free-floating sections were permeabilized with 0.2% Triton X-100 and 0.5% BSA in 0.1 M PBS for 30 minutes and then incubated overnight at 4-C with primary antibody against P2X 7 R (1:200; Alomone Laboratory). Sections were then sequentially incubated with Alexa Fluor-conjugated 488 anti-rabbit IgG (1:100; Molecular Probes) at RT for 2 hours in the dark. For double immunofluorescence immunohistochemistry, free-floating sections were incubated overnight at 4-C with a mixture of 2 primary antibodies: P2X 7 R in combination with AA (1:500; Abcam, Cambridge, MA), OX-42 (1:200; Serotec, Oxford, UK), or GFAP (1:500; Sigma). Sections were then incubated in a mixture of Alexa Fluor-conjugated 488 anti-rabbit IgG (1:100; Molecular Probes) and Alexa Fluor 594-conjugated anti-mouse IgG (1:100; Molecular Probes) at RT for 2 hours in the dark. Stained sections were examined under a Zeiss Axioplan 2 fluorescent microscope and images were acquired with a DVC camera (Diagnostic Instruments, Sterling Heights, MI). For quantification of P2X 7 R immunoreactivity, mean gray level of immunoreactivity was measured and quantified using Northern Eclipse software (Empix Imaging, Mississauga, ON, Canada) (20) . All quantitative analyses were carried out in a blinded manner.
Statistical Analysis
All results are presented as mean T standard error of mean. Statistical significance (p G 0.05) was evaluated using Student t-test or one-way analysis of variance followed by Student-Newman-Keuls multiple comparison test when applicable (GraphPad Prism 3.0; San Diego, CA).
RESULTS
P2X 7 R Expression in Microglia from Patients With Alzheimer Disease and Nondemented Individuals
RT-PCR was carried out for expression of P2X 7 R in microglia obtained from 14 individuals. Of these, 6 were confirmed as AD and 8 showed no diagnosis for AD symptoms and were confirmed as ND (see BMaterials and Methods[). Representative band intensities for microglial P2X 7 R expressions are shown for one ND case and one AD case (Fig. 1A) ; also shown is GAPDH as a reaction standard. In general, microglia obtained from ND individuals showed weak band intensity for P2X 7 R, indicating a low constitutive expression for this subtype of purinergic receptor. However, microglia from all AD cases showed strong expressions for P2X 7 R.
The results from semiquantitative analysis of band intensities are presented in Figure 1B showing relative mRNA levels of P2X 7 R in AD and ND microglia. Overall, the expression of P2X 7 R was increased by 70% in AD microglia (n = 6 cases) compared with ND cells (n = 8 cases). Immunohistochemical procedures were also applied to examine expression of P2X 7 R protein in AD brain sections (Fig. 2) . P2X 7 R immunoreactivity was observed throughout sections ( Fig. 2A, blue staining) but was prominently expressed in association with AA plaques (Fig 2A, brown staining) . Weak P2X 7 R immunoreactivity was seen on cells with morphologic appearance of microglia throughout the tissue sections in both white and grey matter. Using an antibody to HLA-DR to identify microglia, stronger P2X 7 R staining correlated with stronger HLA-DR immunoreactivity (Fig. 2B) . Staining for P2X 7 R was only observed on cells that had immunoreactivity for HLA-DR and had the morphology of microglia. Little or no evidence for P2X 7 R immunoreactivity was found in ND brain sections (data not shown).
P2X 7 R Expression in AA 1-42 -Treated and Untreated Human Microglia
AD brains are characterized by senile plaques of fibrillar AA 1-42 peptide and neurofibrillary tangles. We next examined the effects of exposure of cultured fetal human microglia to AA 1-42 (at 5 KM for 18 hours); 2 controls were used with one group treated with PBS and another group treated with reverse peptide AA 42-1 (at 5 KM for 18 hours). The representative results from a single RT-PCR assay for P2X 7 R are presented in Figure 3A . Human microglia exposed to PBS or to AA 42-1 exhibited a low level of band intensity for P2X 7 R, whereas AA 1-42 -treated cells showed a robust expression for this subtype purinergic receptor (Fig. 3A) . GAPDH was used as a reaction standard (Fig. 3A, lower panel) .
The quantification of results is presented in Figure 3B . Treatment of human microglia with AA 1-42 peptide (n = 6) significantly increased P2X 7 R expression (by 106%) relative to PBS control (n = 6) and by 76 % compared with reverse peptide (n = 5).
Functional Responses of P2X 7 R in AA 1-42 -Pretreated and Untreated Human Microglia
It was of interest to determine if P2X 7 R-mediated responses in fetal human microglia were modulated by cellular exposure to AA . This point was studied using the selective P2X 7 R agonist BzATP to elicit entry of Ca 2+ through the nonselective cationic channel associated with this receptor. Human microglial cells were placed in culture medium and grouped as control (no exposure to AA 1-42 peptide), AA 1-42 -treated (exposure to 5 KM peptide for 18 hours), and AA 1-42 -treated in the presence of oxATP (a specific inhibitor of P2X 7 R). In the latter group, oxATP (at 300 KM) was applied 2 hours before, and for the duration of, peptide application.
Representative results are presented in Figure 4A . In microglia pretreated with AA , BzATP (at 300 KM) caused a large increase in [Ca 2+ ] i (measured by the change in wavelength ratio, 340/380 nm), which continued to grow in amplitude to a plateau level at 10 minutes postapplication of the purinergic ligand (n = 32 cells). In the presence of oxATP, the response elicited by BzATP from peptidetreated cells was markedly reduced (n = 18 cells). BzATP evoked a small increase in [Ca 2+ ] i in untreated microglia (control, n = 28 cells). oxATP was effective in abolishing control responses (control + oxATP; n = 27 cells).
Quantification of BzATP-induced Ca 2+ responses with the different treatments was determined by measurement of the peak amplitudes of [Ca 2+ ] i with respect to baseline levels. With AA 1-42 pretreatment (n = 5 experiments; 95 cells), response amplitudes were increased by 145% relative to control (n = 4 experiments; 87 cells) (Fig. 4B) . With oxATP included together with AA in the pretreatment solution (n = 4 experiments; 82 cells), Ca 2+ responses were decreased by 86% relative to peptide alone. oxATP application to control completely blocked BzATP responses (n = 4 experiments, 76 cells).
P2X 7 R Expression in Rat Hippocampus
We next investigated the expression of P2X 7 R in rat hippocampus for 3 different groups of animals: those receiving intrahippocampal injections of PBS, AA , or AA 42-1 . Peptides were injected at 1 nmol with all analyses carried out at 3 days postinjection. Representative RT-PCR is presented in Figure 5A showing a low basal level of P2X 7 R after PBS injection. A considerably enhanced expression of the purinergic receptor was observed with injection of AA , whereas AA 42-1 was associated with a low level of P2X 7 R (Fig. 5A) . A-actin was used as a reaction standard (Fig. 5A, lower panel) . Semiquantitative results for the 3 groups of injected animals (n = 3 for each) are shown in Figure 5B . The expression of P2X 7 R was increased 4-fold in AA 1-42 -injected, relative to PBS or reverse peptideinjected, rat hippocampus.
We also used immunohistochemical procedures to investigate expression of P2X 7 R protein in the dentate gyrus (Fig. 6A , top left panel, portion of superior blade denoted by dotted line). Within the superior blade region, minimal P2X 7 R immunoreactivity was evident at 3 days after injection of PBS (Fig. 6A, top right panel) . However, immunoreactivity for P2X 7 R was markedly elevated in AA 1-42 -but not AA 42-1 -injected animals (Fig. 6A, bottom  panels) . Quantification of P2X 7 R immunoreactivity demonstrates the extent of P2X 7 R immunoreactivity induced with AA 1-42 injection compared with PBS or AA 42-1 -injected animals (Fig. 6B, n = 4 for each group) .
A representative double immunostaining result is presented showing extensive areas of P2X 7 R immunoreactivity in proximity to AA 1-42 deposits (Fig. 6C, left panel) . The morphology of cells expressing P2X 7 R was consistent with microglia. We next used double immunostaining to enable identification of the specific cells that were associated with expression of P2X 7 R. Representative double immunofluorescent staining is presented in Figure 6C for P2X 7 R with OX-42 (microglial marker, middle panel) or GFAP (astrocyte marker, right panel). The results showed colocalization of P2X 7 R and OX-42+ microglia within the hippocampus after AA 1-42 injection (Fig. 6C, middle panel) . Only a small subset of GFAP+ astrocytes was associated with P2X 7 R (Fig. 6C,  right panel) . No colocalization of the purinergic receptor with NeuN+ neurons was observed (data not shown).
DISCUSSION
An important and novel finding from this study is that expression of P2X 7 R is upregulated in microglia in AD, compared with levels in ND, brain. We also report that fetal human microglia stimulated with AA 1-42 peptide exhibit considerably elevated expressions of P2X 7 R relative to control (untreated cells and AA 42-1 ) and show marked increases in [Ca 2+ ] i in response to a P2X 7 R agonist after exposure to peptide. In addition, P2X 7 R was markedly upregulated in AA 1-42 -injected compared with PBS or AA 42-1 -injected rat hippocampus.
Microglia obtained from ND brain show a low level of expression for P2X 7 R; however, considerable upregulation of the purinergic receptor was evident in AD microglia (Fig. 1A) . Semiquantitative RT-PCR (Fig. 1B) indicated an approximate 2-fold increase in mRNA levels in AD, relative to ND, microglia. The constitutive expression of P2X 7 R in ND microglia could be associated with a relatively low basal activation of cells. Microglia in ND brain exhibit a predominantly ramified morphology; however, some ameboidshaped cells were observed (13) . Cells obtained from AD individuals present a primary ameboid morphology (13) . The respective ramified and ameboid morphologies are commonly associated with resting and activated states of microglia (14) .
Cultured fetal human microglia exposed to AA 1-42 (5 KM for 18 hours) exhibited a marked increase in the expression of P2X 7 R compared with PBS or reverse peptidetreated cells. Relative mRNA levels were increased in excess of 2-fold in microglia exposed to AA 1-42 compared with PBS. Together with the results from Figure 1 microglia and peptide-treated cells. These responses were attributed to release of Ca 2+ from endoplasmic reticulum stores subsequent to ATP binding to P2Y subtype receptors. An important point is that these experiments used ATP at 100 KM, a level insufficient to activate P2X 7 R in human microglia (3) .
Expression of P2X 7 R was markedly upregulated in AA 1-42 -injected rat hippocampus compared with PBS or reverse peptide-injected brains. Double immunostaining procedures showed microglia were the primary cell type expressing P2X 7 R. A small degree of P2X 7 R immunoreactivity was associated with astrocytes, whereas neurons exhibited no expression for the purinergic receptor. Although intrahippocampal injection of AA 1-42 represents a simplified model of AD brain, the in vivo results support roles for P2X 7 R in mediating microglial responses to peptide stimulation.
At present, the mechanisms underlying stimulusinduced upregulation in expressions of P2X 7 R are not known (21) . A critical point in the function of P2X 7 R is that the receptor ion channel complex is only operational with high levels of extracellular ATP, generally in excess of 1 mM (3, 22, 23) . This would suggest activation of P2X 7 R is associated with pathologic conditions associated with elevated ATP levels such as could occur with damaged neurons (24) or with chronically activated glia (25, 26) . It is known that ATP can enhance P2X 7 R-mediated responses in microglia and other inflammatory cells (27) . In terms of the present results, enhanced expression of P2X 7 R in AD microglia or in vivo in peptide-injected brain could be the result of ATP released from cell injury or stimulated glia in the tissue.
Our findings with AA 1-42 stimulation of fetal human microglia could suggest an autocrine signaling role for ATP in a manner similar to that reported for lipopolysaccharide (LPS)-stimulated microglia (28) . We also found that fetal human microglia treated with the LPS exhibit increased expressions of P2X 7 R (data not shown). This result could be consistent with a common activating factor such as ATP in the induction of P2X 7 R in microglia stimulated by AA or LPS. Interestingly, coculture studies have found activated astrocytes release ATP, which in turn mediated activation of P2X 7 R in microglia (29) . Our results do not exclude the possibility that AA 1-42 induces expression of P2X 7 R by means other than elevating levels of ATP. For example, IL-1A is reported to transiently enhance the expression of P2X 7 R in glia (30) . Overall, multiple factors may engage in regulating P2X 7 R, including elevated levels of extracellular ATP from damaged cells, ATP arising from paracrine sources, and the presence of proinflammatory cytokines. Because one downstream effect of P2X 7 R activation is cell apoptosis (28, 31) , regulation of this subtype of purinergic receptor is likely under strict control.
It is important to note that P2X 7 R-mediated microglial activation can influence the inflammatory environment in the pathogenesis of AD. Activation of the P2X 7 R has been shown to modulate the production of proinflammatory cytokines from AA or LPS-stimulated human microglia and macrophages (26) . The P2X 7 R ligand BzATP enhanced secretion of IL-1A with both peptide and LPS stimulation but TNF-> was only increased with the latter stimulus. Much of the deleterious effects mediated by P2X 7 R responses in microglia are the result of potent neurotoxic factors produced by P2X 7 R-dependent pathways. Previous work has reported enhancement of P2X 7 R activation leads to increased production of proinflammatory cytokines (26, 32) , superoxide anion (10), excitatory amino acids (33) , and matrix metalloproteinases (34) . All of these factors have been implicated in causing neuronal damage in the AD brain (35) . It is possible that enhanced P2X 7 R expression could contribute to the increased levels of inflammatory factors such as TNF->, IL-1A, and iNOS measured in AD compared with ND brains (36) .
Overall, our results suggest the involvement of P2X 7 R in mediating inflammatory responses in AD brain. However, a proviso is that although P2X 7 R expression in microglia is enhanced in the AD brain or by exposure to AA , elevated ATP concentrations in excess of 1 mM may be required for activation of this receptor (3, 5) . Such high levels of ATP would likely be associated with a localized environment of cellular damage and chronically activated glia responding to a brain insult such as deposits of amyloid peptide. An important question for future study is whether animal models of AD show sustained upregulation of P2X 7 R with long-duration applications of low (nM) levels of AA peptide.
